皮质醇21-硫酸盐 | 1253-43-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 皮质醇21-硫酸盐
• 英文名称: 4-pregnene-11β,17α,21-triol-3,20-dione 21-sulfate
• 英文别名: 11β,17,21-trihydroxy-4-pregnen-3,20-dione 21-sulfate；4-pregnen-11β,17α,21-triol-3,20-dione-21-SO4；4-pregnen-11β,17,21-triol-3,20-dione-21-sulfate；cortisol 21-sulfate；cortisol-21-sulfate；Cortisol-21-sulfonsaeure；[2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] hydrogen sulfate
• CAS: 1253-43-6
• 化学式: C₂₁H₃₀O₈S
• 分子量: 442.53
• InChiKey: JOVLCJDINAUYJW-VWUMJDOOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  147
• 氢给体数：
  3
• 氢受体数：
  8

制备方法与用途

生物活性

Cortisol sulfate（皮质醇21硫酸酯，HY-N0583的一种代谢物）是细胞内运皮质激素蛋白的特异性配体。

体内研究

皮质醇硫酸酯（3 mg；腹肌注射；每两天一次；持续2-7周）直接作用于中枢神经系统，影响行为表现。

具体实验结果如下：

• 动物模型：雄性Wistar-King大鼠
• 剂量：3 mg
• 给药方式：腹肌注射，每两天一次，持续2-7周
• 结果：治疗在断奶后不久（出生后第21-24天）开始时，对动物的探索行为（行走和站立）产生了显著刺激作用。

反应信息

• 作为产物：
  描述：

  氢化可的松 在 三氧化硫 、 三乙胺 作用下， 生成 皮质醇21-硫酸盐
  参考文献：
  名称：

  类固醇共轭物IV。用三乙胺-三氧化硫制备甾族硫酸盐。

  摘要：

  DOI：

  10.1016/s0039-128x(68)80079-0

文献信息

• Method for the diagnosis and prognosis of cancer
  申请人：THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES

  公开号：US10393745B2

  公开（公告）日：2019-08-27

  The present invention provides methods and materials for diagnosing cancer in an individual using a tissue, blood or urine sample from the patient. Specifically, the disclosed method comprises determining the level of one or more metabolite selected from the group consisting of creatine riboside, metabolite 561+, Cortisol sulfate and N-acetylneuraminic acid. The present invention also provides a method for determining the prognosis of a cancer patient by determining the level of one or more metabolite selected from the group consisting of creatine riboside, metabolite 561+, Cortisol sulfate and N-acetylneuraminic acid. Also provided are kits for detecting cancer or determining the prognosis of a cancer patient.

  本发明提供了利用患者的组织、血液或尿液样本诊断癌症的方法和材料。具体来说，所公开的方法包括测定选自肌酸核苷、代谢物 561+、硫酸皮质醇和 N-乙酰神经氨酸组的一种或多种代谢物的水平。本发明还提供了一种通过测定选自由肌酸核苷、代谢物 561+、皮质醇硫酸盐和 N-乙酰神经氨酸组成的组中的一种或多种代谢物的水平来确定癌症患者预后的方法。还提供了用于检测癌症或确定癌症患者预后的试剂盒。
• METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF CANCER
  申请人：The United States of America, as represented by The Secretary, Department of Health and Human Services

  公开号：EP3019871A2

  公开（公告）日：2016-05-18
• IMPLANTS CONTAINING DISULFIRAM AND AN ANTI-INFLAMMATORY AGENT
  申请人：Gooberman Lance L.

  公开号：US20100196436A1

  公开（公告）日：2010-08-05

  The present invention provides an implantable composition which contains disulfiram, an anti-inflammatory agent, and optionally a pharmaceutically acceptable carrier. Methods of making the implants, and methods of using the implants to treat alcoholism and opioid dependency are also disclosed.
• PHARMACEUTICAL DELIVERY SYSTEMS FOR TREATMENT OF SUBSTANCE ABUSE AND OTHER ADDICTIONS
  申请人：Gooberman Lance L.

  公开号：US20100311704A1

  公开（公告）日：2010-12-09

  Disclosed are injectable pharmaceutical compositions that contain a therapeutically effective amount of an anti-addictive agent, an anti-inflammatory agent, and a pharmaceutically acceptable liquid carrier, methods of making the compositions, and uses thereof for treating addictions including substance abuse (or addiction to an abused substance) and addictive or compulsive behavior, by administering the composition to a subject in need thereof.
• Degradable networks for sustained release and controlled release depot drug delivery applications
  申请人：Gooberman Lance L.

  公开号：US20120164207A1

  公开（公告）日：2012-06-28

  Provided herein is a controlled release and/or sustained release depot drug delivery system, comprising, a biodegradable polymer coating and an API coated with the biodegradable polymer coating, wherein a quantity of API coated with biodegradable polymer is effective to be released from the biodegradable polymer coating over a prolonged period of time.